What is Eligo Bioscience?
Eligo Bioscience is at the forefront of in vivo gene editing, specifically targeting the microbiome to address diseases with high unmet medical needs. The company's proprietary GEM (Gene Editing of the Microbiome) platform enables precise editing of bacterial genes within the microbiome. Founded by distinguished scientists, Eligo Bioscience is poised to transform healthcare by offering targeted therapeutic interventions through advanced genetic engineering of the gut flora.
How much funding has Eligo Bioscience raised?
Eligo Bioscience has raised a total of $55M across 3 funding rounds:
Series A
$20M
Series B
$30M
Grant
$5M
Series A (2017): $20M with participation from Khosla Ventures and Seventure Partners
Series B (2023): $30M led by Bpifrance, Sanofi Ventures, Seventure Partners, and Khosla Ventures
Grant (2025): $5M supported by Ministry for Europe and Foreign Affairs
Key Investors in Eligo Bioscience
Khosla Ventures
Khosla Ventures is a venture capital firm known for investing in disruptive technologies across various sectors, including health and biotechnology, providing strategic advice to its portfolio companies.
Seventure Partners
Seventure Partners is an investment firm that actively supports innovative companies in life sciences and digital technologies, focusing on health and biotechnology ventures.
Bpifrance
Bpifrance is a French public investment bank that finances and supports companies at all stages of their development, with a focus on innovation and international growth, including in the life sciences sector.
What's next for Eligo Bioscience?
The recent major strategic investment signals a pivotal growth phase for Eligo Bioscience, likely enabling the company to accelerate its research and development pipeline, expand its clinical trials, and scale its operations. This capital infusion is expected to bolster its efforts in bringing its groundbreaking microbiome gene editing solutions to market, potentially establishing new standards of care for a range of challenging diseases.
See full Eligo Bioscience company page
